The results of our study for primary composite outcome (cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke) are compatible with those of previous randomized controlled trials (i.e., SAVOR [12], EXAMINE [13], and TECOS [14] trials), which indicated that short-term use of DPP-4 inhibitors have a neutral effect on cardiovascular death, myocardial infarction and stroke. The gene discussed is DPP4; the disease is myocardial infarction.